Arrowhead Pharmaceuticals vs Kiniksa Pharmaceuticals International
ARWR and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and KNSA compare
Kiniksa Pharmaceuticals International is the larger company, worth 1.7 times as much as Arrowhead Pharmaceuticals ($14.4B against $8.5B).
Kiniksa Pharmaceuticals International grew revenue faster over the last twelve months (58.9% versus 16.8% for Arrowhead Pharmaceuticals).
Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 9.6% compared with −47.8% at Arrowhead Pharmaceuticals.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | KNSA |
|---|---|---|
| Size and price | ||
| Market cap | $8.5B | $14.4B |
| Share price | $59.90 | $92.24 |
| Change, 1 year | 48.7% | 147% |
| Change, 5 years | −25.8% | 526% |
| Beta (5Y) | 1.73 | 0.34 |
| Employees | 711 | 366 |
| StockData Score | ||
| Total score | 5 | 14 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 95.1× |
| P/S | 12.6× (better) | 17.1× |
| P/B | 18.2× (better) | 22.0× |
| EV/EBITDA | – | 136× |
| P/FCF | – | 78.7× |
| FCF yield | −0.89% | 1.3% (better) |
| Fair value | $32.22 | $11.65 |
| Margin of safety | −85.9% (better) | −692% |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 58.9% (better) |
| Revenue growth, 5Y average | 56.6% | – |
| Net income growth (TTM) | – | 1584% |
| EPS growth (TTM) | – | 2325% |
| Profitability | ||
| Gross margin | – | 89.8% |
| Operating margin | −33.8% | 11.9% (better) |
| Net margin | −47.8% | 9.6% (better) |
| FCF margin | −11.2% | 21.7% (better) |
| Return on equity | −64.8% | 14.0% (better) |
| Return on invested capital | – | 44.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −2.4× | – |
| Current ratio | 5.90 (better) | 3.90 |
| Altman Z-score | 2.56 | 37.02 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.6% | 30.1% |
| Held by insiders | 4.0% | 4.7% |
| Insider net buying, 12 months | −$37.3M (better) | −$44.8M |
| Short interest, % of float | 7.9% | 2.5% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.